<DOC>
	<DOCNO>NCT00488059</DOCNO>
	<brief_summary>This 2-arm study evaluate efficacy safety Fuzeon integrase inhibitor expand access program plus optimized background antiviral regimen ( AVR ) HIV-1 infected patient naive Fuzeon integrase inhibitor . In first cohort phase study ( Phase I ) , eligible patient receive Fuzeon 90 mg subcutaneously ( SC ) twice daily confirmation response ( min/max = 8/16 week ) . In Phase II , randomise comparator phase study , responder randomize receive Fuzeon either 90 mg SC twice day 180 mg SC day 16 week . Non-responders virological failure terminate study . The anticipated time study treatment 3-9 month , target sample size 210 individual .</brief_summary>
	<brief_title>A Study Fuzeon ( Enfuvirtide ) With Integrase Inhibitor Plus Optimized Background Treatment-Experienced HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Adult patient , &gt; =18 year age HIV1 infection Triple class treatmentexperienced , Fuzeon integraseinhibitor naive GSS &gt; = 3 ; nucleoside exclude Adverse clinical laboratory experience &gt; ACTG Grade 4 Untreated infection , intercurrent illness , drug toxicity condition contraindicate antiretroviral regimen Malignancy require chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>